A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
Hormone Refractory Prostate Cancer, Bone Metastases
About this trial
This is an interventional treatment trial for Hormone Refractory Prostate Cancer focused on measuring prostate cancer, cisplatin, strontium-89, phase II
Eligibility Criteria
Inclusion Criteria: adenocarcinoma of the prostate life expectancy > 3 months, symptomatic from bone metastases radiologic evidence of metastatic bone disease stable level of pain control >18 years ability to complete assessments prior treatment (chemo) > 4 weeks previous discontinued anti-androgens for > 4 weeks Exclusion Criteria: prior strontium therapy previous hemibody RT within 6 weeks previous cytotoxic chemotherapy within 4 weeks use of bisphosphonate medications within 4 weeks change in steroid dose within 4 weeks active uncontrolled infection impending or present spinal cord compression significant neurological disorder impending pathological fracture severe urinary incontinence
Sites / Locations
- Tom Baker Cancer Centre
- BC Cancer Agency